论文部分内容阅读
口服聚乙烯吡咯酮(PVP)治疗31例慢性肾功能衰竭(CRF)患者。治疗前BUN22.09±9.54mmol/L,Scr618.28±217.36μmol/L。口服PVP治疗2周BUN和Scr分别下降至16.89±7.87mmol/L和496.71±191.18μmol/L,与治疗前比较有显著差异(P<0.05)。大多数病人症状明显改善,且无明显不良反应。
Oral Polyvinylpyrrolidone (PVP) in 31 patients with chronic renal failure (CRF). Before treatment BUN22.09 ± 9.54mmol / L, Scr618.28 ± 217.36μmol / L. The levels of BUN and Scr decreased to 16.89 ± 7.87mmol / L and 496.71 ± 191.18μmol / L, respectively, two weeks after oral administration of PVP, which were significantly different from those before treatment (P <0.05). The symptoms of most patients were significantly improved with no apparent adverse reactions.